RecruitingPHASE1, PHASE2NCT05765084

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Antwerp
Principal Investigator
Zwi N Berneman, MD, PhD
Antwerp University Hospital, Division of Hematology and Center for Cell Therapy and Regenerative Medicine
Intervention
Dendritic cell vaccination(biological)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2026

Study locations (3)

Collaborators

Algemeen Ziekenhuis Maria Middelares · Vitaz · Kom Op Tegen Kanker · Roche Pharma AG

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05765084 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma →

← Back to all trials